94 related articles for article (PubMed ID: 33324208)
1. The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies.
Mora J; Castañeda A; Flores MA; Santa-María V; Garraus M; Gorostegui M; Simao M; Perez-Jaume S; Mañe S
Front Pharmacol; 2020; 11():575009. PubMed ID: 33324208
[No Abstract] [Full Text] [Related]
2. Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review.
Żebrowska U; Balwierz W; Wechowski J; Wieczorek A
Target Oncol; 2024 Mar; 19(2):143-159. PubMed ID: 38401028
[TBL] [Abstract][Full Text] [Related]
3. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Muñoz JP; Larrosa C; Chamorro S; Perez-Jaume S; Simao M; Sanchez-Sierra N; Varo A; Gorostegui M; Castañeda A; Garraus M; Lopez-Miralles S; Mora J
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835531
[TBL] [Abstract][Full Text] [Related]
4. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
Desai AV; Gilman AL; Ozkaynak MF; Naranjo A; London WB; Tenney SC; Diccianni M; Hank JA; Parisi MT; Shulkin BL; Smith M; Moscow JA; Shimada H; Matthay KK; Cohn SL; Maris JM; Bagatell R; Sondel PM; Park JR; Yu AL
J Clin Oncol; 2022 Dec; 40(35):4107-4118. PubMed ID: 35839426
[TBL] [Abstract][Full Text] [Related]
5. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
Mora J; Modak S; Kinsey J; Ragsdale CE; Lazarus HM
Int J Cancer; 2024 Apr; 154(8):1340-1364. PubMed ID: 38108214
[TBL] [Abstract][Full Text] [Related]
6. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System.
Wang G; Wang J; Du R; Wang Y; Li Z
Paediatr Drugs; 2024 Mar; 26(2):175-185. PubMed ID: 38153627
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3.
Eichholz T; Heubach F; Arendt AM; Seitz C; Brecht IB; Ebinger M; Flaadt T; Süsskind D; Richter L; Hülsenbeck I; Zerweck L; Göricke S; Paulsen F; Dombrowski F; Flotho C; Schönberger S; Ketteler P; Schulte J; Lang P
Cancer Immunol Immunother; 2024 Jan; 73(1):19. PubMed ID: 38240863
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China.
Yu U; Xu H; Chen S; Yi M; Liu C; Zhang X; Wang C; Song J; Gan Y; Wang J; Wang Y; Zhang Q; Sun J; Xia B; Zhang G; Li C; Wen F; Liu S; Yuan X
Cancer Control; 2023; 30():10732748231187837. PubMed ID: 37575028
[TBL] [Abstract][Full Text] [Related]
9. A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood.
Keyel ME; Furr KL; Kang MH; Reynolds CP
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834874
[TBL] [Abstract][Full Text] [Related]
10. Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.
Gorostegui M; Muñoz JP; Perez-Jaume S; Simao-Rafael M; Larrosa C; Garraus M; Salvador N; Lavarino C; Krauel L; Mañe S; Castañeda A; Mora J
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730688
[TBL] [Abstract][Full Text] [Related]
11. The Impact of
Park HJ; Choi JY; Kim BK; Hong KT; Kim HY; Kim IH; Cheon GJ; Cheon JE; Park SH; Kang HJ
Children (Basel); 2023 Dec; 10(12):. PubMed ID: 38136138
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of dinutuximab in the treatment of neuroblastoma: A review.
Mohd AB; Mohd OB; Alabdallat YJ; Al Dwairy SY; Ghannam RA; Hanaqtah BM; Albakri KA
J Res Med Sci; 2023; 28():71. PubMed ID: 38116487
[TBL] [Abstract][Full Text] [Related]
13. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Oesterheld J; Ferguson W; Kraveka JM; Bergendahl G; Clinch T; Lorenzi E; Berry D; Wada RK; Isakoff MS; Eslin DE; Brown VI; Roberts W; Zage P; Harrod VL; Mitchell DS; Hanson D; Saulnier Sholler GL
J Clin Oncol; 2024 Jan; 42(1):90-102. PubMed ID: 37883734
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of dinutuximab β for the treatment of high-risk neuroblastoma in China.
Shen AL; Zhao J; Yu LT; Zhang AA; Wu B; Fang Y; Han YL; Li CS; Li ZL; Gao YJ; Zhang SG
Pediatr Blood Cancer; 2023 Dec; 70(12):e30680. PubMed ID: 37715719
[TBL] [Abstract][Full Text] [Related]
15. Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse.
Flaadt T; Ebinger M; Schreiber M; Ladenstein RL; Simon T; Lode HN; Hero B; Schuhmann MU; Schäfer J; Paulsen F; Timmermann B; Eggert A; Lang P
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834840
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow relapse in stage 4 neuroblastoma of children in Shanghai.
Li H; Zhao J; Yang J; Tang J; Zhang T; Jiang H; Shao J
Am J Cancer Res; 2024; 14(1):145-154. PubMed ID: 38323287
[TBL] [Abstract][Full Text] [Related]
17. Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.
Mora J; Climent A; Roldán M; Flores MC; Varo A; Perez-Jaume S; Jou C; Celma MS; Lazaro JJ; Cheung I; Castañeda A; Gorostegui M; Rodriguez E; Chamorro S; Muñoz JP; Cheung NK
Front Oncol; 2024; 14():1380917. PubMed ID: 38812778
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy.
Gregory K; Hansen D; Penglase R; Apostolopoulos D; Ngian GS; Stevens W; Morrisroe K; Ferdowsi N; Ross L; Walker J; Cooley H; Youssef P; Tymms K; Host L; Proudman S; Moore J; Nikpour M; Sahhar J
Arthritis Rheumatol; 2024 Apr; ():. PubMed ID: 38560777
[TBL] [Abstract][Full Text] [Related]
19. Yoga as a non-pharmacologic therapy to reduce dinutuximab-induced pain in patients with neuroblastoma.
Parisio KN; Kulp T; Heil M; Li Y; Dalton K; McGrath M; Carlowicz C; Donnelly M; Bagatell R; Jubelirer T
Pediatr Blood Cancer; 2024 Apr; 71(4):e30845. PubMed ID: 38192171
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
